sample of publications

• articles 

  • Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model.  NEUROBIOLOGY OF AGING.  96:148-154. 2020
  • Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate.  JOURNAL OF MEDICINAL CHEMISTRY.  63:2638-2655. 2020
  • Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis.  Future Medicinal Chemistry.  11:1703-1720. 2019
  • Tau-centric multitarget approach for alzheimer's disease: Development of first-in-class dual glycogen synthase kinase 3ß and tau-aggregation inhibitors.  JOURNAL OF MEDICINAL CHEMISTRY.  61:7640-7656. 2018
  • Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa.  Molecular Neurodegeneration.  13:19. 2018
  • Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.  138:328-342. 2017
  • Classics in Chemical Neuroscience: Haloperidol.  ACS Chemical Neuroscience.  8:444-453. 2017
  • Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa.  JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY.  32:522-526. 2017